retatrutide clinical data retatrutide is one of the most exciting medications currently being studied for obesity and metabolic disease-but there's one important thing to understand: It is NOT approved yet. I get asked almost daily, “ Retatrutide – The New Weight

hard boiled egg on the side for more protein Smashed avocado and white beans on whole wheat toast Lunch Black bean soup, carrots and hummus Chicken and brown rice bowl with salsa Turkey sandwich on whole wheat bread, carrot sticks, pear Dinner Salmon, baked sweet potato, roasted Brussels sprouts Cabbage and beef skillet, seasoned with rice vinegar and low-sodium soy sauce and served over barley Tofu and pea stir fry Final Considerations Timing of meals and other eating habits may also influence GLP-1 levels

Retatrutide for type 2 diabetes: Phase 2 trial results (36-week study, HbA1c reductions, weight loss) New England Journal of Medicine (2023) Jastreboff AM, et al

LY3437943 is a triagonist peptide activating GLP-1, GIP, and glucagon receptors in concert

provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself

These locations were selected because they provide adequate subcutaneous tissue depth for reliable absorption, easy access for self-administration, and relatively low risk of hitting blood vessels or nerves

Non-alcoholic fatty liver disease (NAFLD) affects an estimated 30% of the global population and is the most common cause of chronic liver disease